‘Everybody’s going to have a lot of losers’: Most biotech investors are getting burned even as fledgling companies are raising money hand-over-fist
|10/12/2018||Posted by BusinessMediaguide.Com under General World News||
- The window for biotech companies to raise money and go public has seemed unending over the past few years.
- Particularly in the past year, private companies have raised staggeringly big early funding rounds before turning around to tap the public markets for even more cash.
- But the bets haven’t always panned out for investors. Of the biotech companies that have gone public in the past six years, fewer than half have generated a positive return, according to a new report.
For fledgling biotechs hoping to find the money to fund their plans to tackle everything from cancer to Alzheimer’s disease, the public read more >>>